Harvard Stem Cell Institute
Progress Report: January 2018 
Illustration of blood cells
Because the bone marrow contains blood system stem cells, transplants of healthy bone marrow are used to treat patients with blood cancers or disorders. Currently, donors undergo multiple days of drug injections in order to mobilize stem cells from the bone marrow to the blood for collection. 

In a recent study, HSCI principal faculty members Jonathan Hoggatt and David Scadden report a novel drug combination that could improve the donation process: when tested in mice, a single injection mobilized stem cells within fifteen minutes.
Photo of Paola Arlotta
HSCI principal faculty member Paola Arlotta has been awarded the George Ledlie Prize by the President and Fellows of Harvard College. As explained in the Harvard Gazette, the prize is given to the Harvard affiliate who "has by research, discovery, or otherwise made the most valuable contribution to science." Arlotta studies embryonic brain development, and most recently pioneered a method of growing three-dimensional brain organoids in laboratory cultures.
Photo of bioengineered heart
In a recent video, The Wall Street Journal focuses on the increasing problem of organ transplants: not only is there a shortage of donor organs, but transplanted organs often fail due to rejection by the patient's immune system. Looking forward, the video highlights the paradigm-changing research of HSCI's Harald Ott. His strategy is to make a scaffold by removing the cells from a donor organ, add cells that are derived from the patient's own stem cells, and then grow the organ in a bioreactor that mimics the environment of the human body.